Quick Navigation: Home | Contact |

Welcome!

Our goal is to generate a better understanding of the signaling processes controlling angiogenesis and lymphangiogenesis.

Publications:

Each abstract opens into a new window in PubMed that you need to close to return to the main site.

  1. (2010) Embryonic vascular endothelial cells are malleable to reprogramming via Prox1 to a lymphatic gene signature.
    BMC Dev Biol. 2010 Jun 28;10:72.
  2. (2010) Nonlinear multicontrast microscopy of hematoxylin-and-eosin-stained histological sections.
    J Biomed Opt. 2010 Mar-Apr;15(2):026018.
  3. (2010) The inositol phosphatase SHIP-1 is negatively regulated by Fli-1 and its loss accelerates leukemogenesis.
    Blood. 2010 Jul 22;116(3):428-36. Epub 2010 May 5.
  4. (2010) Differential proteomic analysis of lymphatic, venous, and arterial endothelial cells extracted from bovine mesenteric vessels.
    Proteomics. 2010 Apr;10(8):1658-72.
  5. (2010) A negative regulatory role for Y1111 on the Tie-2 RTK.
    Cell Signal. 2010 Apr;22(4):676-83. Epub 2009 Dec 21.
  6. (2009) The angiopietin-1-Tie2 pathway prevents rather than promotes pulmonary arterial hypertension in transgenic mice.
    J Exp Med. 2009 Sep 28;206(10):2221-34. Epub 2009 Sep 8.
  7. (2009) Experimental assessment of autologous lymph node transplantation as treatment of postsurgical lymphedema.
    Plast Reconstr Surg. 2009 Sep;124(3):777-86.
  8. (2009) Angiopoietin-1 induced ubiquitylation of Tie2 by c-Cbl is required for internalization and degradation.
    Biochem J. 2009 Aug 18.
  9. (2009) Oligomerized Tie2 localizes to clathrin-coated pits in response to angiopoietin-1.
    Histochem Cell Biol. 2009 Aug;132(2):225-37.
  10. (2008) Transgenic induction of vascular endothelial growth factor-C is strongly angiogenic in mouse embryos but leads to persistent lymphatic hyperplasia in adult tissues.
    Am J Pathol. 2008 Dec;173(6):1891-901.
  11. (2008) Lymphedema Development and Lymphatic Function following Lymph Node Excision in Sheep.
    J Vasc Res. 2009 Jan 21;46(5):426-434.
  12. (2008) Transgenic induction of vascular endothelial growth factor-C is strongly angiogenic in mouse embryos but leads to persistent lymphatic hyperplasia in adult tissues.
    Am J Pathol. 2008 Dec;173(6):1891-901. Epub 2008 Nov 6.
  13. (2008) Acceleration of Diabetic Wound Healing by an Angiopoietin Peptide Mimetic.
    Tissue Eng Part A. 2008 Oct 22.
  14. (2008) An eosinophil immune response characterizes the inflammatory skin disease observed in Tie-2 transgenic mice.
    J Leukoc Biol. 2008 Jul;84(1):59-67. Epub 2008 May 1.
  15. (2008) Vascular endothelial growth factor-mediated decrease in plasma soluble vascular endothelial growth factor receptor-2 levels as a surrogate biomarker for tumor growth.
    Cancer Res. 2008 Jan 15;68(2):521-9.
  16. (2007) Angiopoietin-2 impairs revascularization after limb ischemia.
    Circ Res. 2007 Jul 6;101(1):88-96. Epub 2007 May 31.
  17. (2007) Differential response of lymphatic, venous and arterial endothelial cells to angiopoietin-1 and angiopoietin-2.
    BMC Cell Biology. 2007 Mar 6;8:10.
  18. (2007) Cell-based Angiopoietin-1 Gene Therapy for Acute Lung Injury.
    Am J Respir Crit Care Med. 2007 May 15;175(10):1014-26. Epub 2007 Feb 22.
  19. (2007) The energy sensing LKB1-AMPK pathway regulates p27(kip1) phosphorylation mediating the decision to enter autophagy or apoptosis.
    Nature Cell Biology. 2007 Feb;9(2):218-24. Epub 2007 Jan 21.
  20. (2006) Lymphangiogenesis following obstruction of large postnodal lymphatics in sheep.
    2007 Microvascular Research May;73(3):214-23. Epub 2006 Dec 26.
  21. (2006) Pharmacologic blockade of angiopoietin-2 is efficacious against model hemangiomas in mice.
    J Invest Dermatol. 2006 Oct;126(10):2316-22. Epub 2006 Jun 1.
  22. (2006) Activation of Tie2 by angiopoietin-1 and angiopoietin-2 results in their release and receptor internalization.
    J Cell Sci. 2006 Sep 1;119(Pt 17):3551-60. Epub 2006 Aug 8.
  23. (2006)Transgenic expression of Angiopoietin 1 in the liver leads to changes in lymphatic and blood vessel architecture.
    Biochem Biophys Res Commun. 2006 Jul 14;345(4):1299-307. Epub 2006 May 4.
  24. (2006) Hepatocyte growth factor mediates angiopoietin-induced smooth muscle cell recruitment.
    Blood. 2006 Aug 15;108(4):1260-6. Epub 2006 Apr 25.
  25. (2006) Chronic systemic delivery of angiopoietin-2 reveals a possible independent angiogenic effect.
    Am J Physiol Heart Circ Physiol. 2006 Aug;291(2):H948-56. Epub 2006 Apr 14.
  26. (2005) Heterogeneity of Tie2 expression in tumor microcirculation: influence of cancer type, implantation site, and response to therapy.
    Am J Pathol. 2005 Dec;167(6):1753-62.
  27. (2005) Loss of Tie2 receptor compromises embryonic stem cell-derived endothelial but not hematopoietic cell survival.
    Blood. 2006 Feb 1;107(3):1207-13. Epub 2005 Oct 11.
  28. (2005) Problems with co-funding in Canada.
    Science. 2005 Jun 24;308(5730):1867.
  29. (2005)Gene expression analysis of Tek/Tie2 signaling.
    Physiol Genomics. 2005 Jul 14;22(2):257-67. Epub 2005 May 17.
  30. (2005) Selective role of a distinct tyrosine residue on Tie2 in heart development and early hematopoiesis.
    Mol Cell Biol. 2005 Jun;25(11):4693-702.
  31. (2005) Dok-R mediates attenuation of epidermal growth factor-dependent mitogen-activated protein kinase and Akt activation through processive recruitment of c-Src and Csk.
    Mol Cell Biol. 2005 May;25(9):3831-41.
  32. (2005)A cyclosporine-sensitive psoriasis-like disease produced in Tie2 transgenic mice.
    Am J Pathol. 2005 Mar;166(3):843-55.
  33. (2005) Vascular-specific growth factor angiopoietin 1 is involved in the organization of neuronal processes.
    J Comp Neurol. 2005 Feb 14;482(3):244-56.
  34. (2005) Genetic heterogeneity of the vasculogenic phenotype parallels angiogenesis; Implications for cellular surrogate marker analysis of antiangiogenesis.
    Cancer Cell. 2005 Jan;7(1):101-11.
  35. (2004)Functional inhibition of secreted angiopoietin: a novel role for angiopoietin 1 in coronary vessel patterning.
    CBiochem Biophys Res Commun. 2004 Oct 22;323(3):937-46.
  36. (2004) Angiopoietin-1 causes reversible degradation of the portal microcirculation in mice: implications for treatment of liver disease.
    Am J Pathol. 2004 Sep;165(3):889-99.
  37. (2004) Angiopoietin 1 expression levels in the myocardium direct coronary vessel development.
    Dev Dyn. 2004 Mar;229(3):500-9.
  38. (2004) Inhibition of Tie-2 signaling induces endothelial cell apoptosis, decreases Akt signaling, and induces endothelial cell expression of the endogenous anti-angiogenic molecule, thrombospondin-1.
    Cancer Biol Ther. 2004 Apr;3(4):402-5. Epub 2004 Apr 29.
  39. (2004) Molecular mechanisms in lymphangiogenesis: model systems and implications in human disease.
    Clin Genetics. 2003 Oct;64(4):282-92.
  40. (2003) Dok-R binds c-Abl and regulates Abl kinase activity and mediates cytoskeletal reorganization.
    J Biol Chem. 2003 Aug 8;278(32):30170-9. Epub 2003 May 30.
  41. (2003) Angiogenic actions of angiopoietin-1 require endothelium-derived nitric oxide.
    Am J Pathol. 2003 Jun;162(6):1927-36.
  42. (2003) “A Unique autophosphorylation site on Tie2/Tek mediates Dok-R PTB domain binding and function”. Molecular & Cellular Biology 23:2658-2668. Senior Responsible Author
  43. (2002) “Imatinib Mesylate (ST1571) reduces Bcr-Abl-Mediated vascular endothelial growth factor secretion in chronic myelogenous leukemia.
    Molecular Cancer Research. 2:89-95.
  44. (2002). "The angiopoietins and Tie2/Tek: adding to the complexity of cardiovlar development."
    Semin Cell Dev Biol. PMID: 11969368 [PubMed - in process]
  45. (2002). "A role for survivin in chemoresistance of endothelial cells ated by VEGF."
    Proc Natl Acad Sci U S A. 99(7):4349-54.
  46. (2001)."Multiple ErbB-2/Neu phosphorylation sites mediate transformation through distinct effector proteins".
    Journal of Biological Chemist76:38921-38928.
  47. (2001)."VEGF-C signaling pathways through VEGFR-2 and VEGFR-3 in vasculoangiogenesis and hematopoiesis".
    Blood 96:3793-3800.
  48. (2001). "Dok-R plays a pivotal role in Angiopoietin-1-dependent cell migration through recruitment and activation of Pak".
    EMBO. 20:5919-5928.
  49. (2001)."Rescue of the early vascular defects in Tek/Tie2 null mice reveals an essential survival function".
    EMBO reports 2:438-445.
  50. (2001)."Biological actions of Angiopoietin-2 in a fibrin-matrix model of angiogenesis is associated with activation of Tie2".
    Cardiovascular Research 49:659-670
  51. (2001). " Tie receptors: new modulators of angiogenic and lymphangiogenic responses."
    Nat Rev Mol Cell Biol.2257-67. Review.
  52. (2000). "Epo regulates erythroid proliferation and differentiation through distinct signaling pathways: implication for erythropoiesis and Friend virus-induced erythroleukemia". Oncogene 19:2296-2304.
  53. (2000). "VEGF-C signaling pathways through VEGFR-2 and VEGFR-3 in vasculoangiogenesis and hematopoiesis."
    Blood. 2000 Dec 1;9):3793-800.
  54. (2000). "Tek/Tie2 signaling: new and old partners.
    Cancer Metastasis Rev."19):13-7. Review.
  55. (1999)."The SH2 inositol 5-phosphatase, Ship1 is recruited in an SH2-dependent manner to the erythropoietin receptor".
    Journal of Biological Chemistry 275:4398-4406.
  56. (1999)."Functions of Tie1 and Tie2 receptor tyrosine kinases in vascular development".
    Current Topics in Microbiology and Immuno. 237:159-172.
  57. (1999)."A murine model of hereditary hemorrhagic telangiectasia".
    Journal of Clinical Investigation 104:1343-1351.
  58. (1999)."Recruitment of Dok-R to the EGF receptor through its PTB domain is required for attenuation of Erk MAP kinase activation".
    Current Biology 9:1057-1060.
  59. (1999)."Identification of Tek/Tie2 binding partners. Binding to a multifunctional docking site mediates cell survival and migration".
    Journal of Biological Chemistry 274:30896-905.
  60. (1999)."SHIP is a negative regulator of growth factor receptor-mediated PKB/Akt activation and myeloid cell survival".
    Genes & Development 3:786-791.
  61. (1999). "Lymphatic endothelial tumors induced by intraperitoneal injection of incomplete Freund's adjuvant". Experimental Cell Research 246:368-75.
  62. (1998)."Critical role of the TIE2 endothelial cell receptor in the development of definitive hematopoiesis".
    Iity 9:677-686.
  63. (1998)."Conditional transgene expression in endothelial cells".
    Transgenic Research 7:421-427.
  64. (1998)."Cardiovascular failure in mouse embryos deficient in VEGF receptor-3".
    Science 282:946-949.
  65. (1998)."Assignment of the Dokr gene to mouse chromosome 14D2-D3 by fluorescence in situ hybridization".
    Genomics 53:413-414.
  66. (1998)."The inositol polyphosphate 5-phosphatase ship is a crucial negative regulator of B cell antigen receptor signaling".
    Journal of Experimental Medicine 188:1333-1342.
  67. (1998)."Molecular cloning of multiple isoforms of synaptojanin 2 and assignment of the gene to mouse chromosome 17A2-3.1.
    Biochemical and Biophysical Research Communications 247:116-122.
  68. (1998)."The Tek/Tie-2 receptor signals through a novel Dok-related docking protein, Dok-R.
    Oncogene 17:1097-1108.
  69. (1998)."The SH2-containing inositol polyphosphate 5-phosphatase, ship, is expressed during hematopoiesis and spermatogenesis".
    Blood 2753-2759.
  70. (1997)."Molecular cloning and chromosomal localization in human and mouse of the SH2-containing inositol phosphatase, INPP5D (SHIP)".
    Genomics 39:109-112.
  71. (1996). "The Tie promoter directs endothelial specific gene expression in vivo". Blood 86:1828-1835.
  72. (1995)."Vascularization of the mouse embryo: A study of flk-1, tek, tie and vascular endothelial growth factor expression during development".
    Developmental Dynamics 203:80-92.
  73. (1995). "Expression of the FLT4 receptor tyrosine kinase becomes restricted to endothelium of lymphatic vessels and some high endothelial venules during development." Proceedings of the National Academy of Science USA 92: 3566-3570.
  74. (1994)."Assignment of the endothelial-specific protein receptor tyrosine kinase gene (TEK) to human chromosome 9p21".
    Genomics 23:512-513.
  75. (1994)."Dominant-negative and targeted null mutations in the endothelial receptor tyrosine kinase, tek, reveal a critical role in vasculogenesis of the embryo". Genes & Development 8:1897-1909.